Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.28, indicating a +1.14% shift from the previous trading day.
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street
Last year, Viking Therapeutics (VKTX 1.83%), a mid-cap biotech, attracted the market's attention thanks to excellent midstage clinical trial results. The company's shares soared in late February 2024, but, unfortunately, they have been southbound since then.
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy?
Viking Therapeutics (VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may eventually rake in significant revenue from the anti-obesity market. It has demonstrated encouraging results in clinical trials; however, it isn't approved just yet.
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from the preceding trading day.
Viking Therapeutics: No Buyout Needed Now
Viking Therapeutics' hit yearly lows despite strong sector expectations, as it enters pivotal trials for obesity drugs. The biotech announced a production deal with CordenPharma, signaling confidence in FDA approval and eliminating the need for capital-intensive manufacturing facilities. The $150 million prepayment deal with CordenPharma ensures production capacity ensures production capacity for 1 billion oral tablets and billions in annual revenues.
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
Viking Therapeutics' new contract is a game changer. Here's how much money it could bring in.
Viking has found a manufacturing partner, removing a key overhang on the stock.
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.
Viking Therapeutics Is Ready For A Standalone Future
Viking Therapeutics announced a supply deal with CordenPharma that sets it up for a standalone path to the obesity market. The deal covers a substantial supply of both the subcutaneous and oral VK2735. The probability of a buyout is not zero, but I believe it is now greatly reduced. And that is a good thing.
Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade)
The sell-off in unprofitable stocks has hit tech and growth sectors hard, with investors seeking safety in healthcare and consumer staples. Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity. VKTX's $900M cash reserves and sufficient liquidity mitigate near-term funding risks, crucial amid current market uncertainties and lack of partnerships.
